Kazia Therapeutics Limite... (KZIA)
NASDAQ: KZIA
· Real-Time Price · USD
9.43
0.38 (4.20%)
At close: Jun 17, 2025, 10:48 AM
Company Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs.
Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma.
It is also developing EVT801, an investigational new drug for various forms of cancer.
The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017.
Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Kazia Therapeutics Limited
| Country | AU |
| IPO Date | Jan 6, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. John Edwin Friend II, M.D. |
Contact Details
Address: Three International Towers Sydney, NSW AU | |
| Website | https://www.kaziatherapeutics.com |
Stock Details
| Ticker Symbol | KZIA |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001075880 |
| CUSIP Number | 48669G303 |
| ISIN Number | US48669G1058 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John Edwin Friend II, M.D. | Chief Executive Officer, MD & Director |
| Elissa C. Hansen ACSA, B.Com., B.Comm, FCIS, Gad Dip ACG, GAI, GAIC | Company Secretary |
| Jeffrey Bonacorda | Vice President of Finance & Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 13, 2025 | SCHEDULE 13G | Filing |
| Jun 12, 2025 | SCHEDULE 13G | Filing |
| Jun 11, 2025 | 424B3 | Filing |
| Jun 11, 2025 | 424B3 | Filing |
| Jun 11, 2025 | 424B3 | Filing |
| Jun 11, 2025 | 6-K | Filing |
| Jun 10, 2025 | 424B3 | Filing |
| Jun 10, 2025 | 424B3 | Filing |
| Jun 10, 2025 | 424B3 | Filing |
| Jun 10, 2025 | 6-K | Filing |